

BNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2 S1 and S2

R. Camille Brewer¹, Nitya S. Ramadoss¹, Lauren J. Lahey²,
William H. Robinson^{1,*}, Tobias V. Lanz^{1,3,*}

Affiliations

¹Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, 269 Campus Drive, Stanford, CA 94305, United States, and the VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304, United States

²Biophysics Program, Stanford University, ChEM-H Building, 290 Jane Stanford Way, Stanford, CA 94305

³Department of Neurology, Mannheim Center for Translational Neurosciences (MCTN), Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

*equal contributions, corresponding authors


The first ever messenger RNA (mRNA) vaccines received emergency approvals in December 2020 and are highly protective against SARS-CoV-2¹⁻³. However, the contribution of each dose to the generation of antibodies against SARS-CoV-2 spike (S) protein and the degree of protection against novel variants, including delta, warrant further study. Here, we investigated the B cell response to the BNT162b2 vaccine by integrating repertoire analysis with single-cell transcriptomics of B cells from serial blood collections pre- and post-vaccination. The first vaccine dose elicits highly mutated IgA⁺ plasmablasts against the S protein subunit S2 at day 7, suggestive of recall of a memory B cell response generated by prior infections with heterologous coronaviruses. On day 21, we observed minimally-mutated IgG⁺ activated switched memory B cells targeting the receptor binding domain (RBD) of the S protein, likely representing a primary response derived from naïve B cells. The B cell response against RBD is specifically boosted by the second vaccine dose, and encodes antibodies that potently neutralize SARS-CoV-2 pseudovirus and partially neutralize novel variants, including delta. These results demonstrate that the first vaccine dose activates a non-neutralizing recall response

35 **predominantly targeting S2, while the second vaccine dose is vital to boosting neutralizing**
36 **anti-S1 RBD B cell responses.**

37 BNT162b2 is one of the two first widely available vaccines that are based on lipid
38 nanoparticle delivery of modified mRNA and is dependent on the host cells for translation and
39 cell surface expression of the SARS-CoV-2 spike (S) protein⁴. S consists of two subunits, S1 and
40 S2. The S1 subunit contains the receptor binding domain (RBD) that binds human ACE2 and
41 initiates viral cell entry, while S2 mediates viral cell membrane fusion^{5,6}. RBD is the target of
42 most neutralizing antibodies found in COVID-19 patients⁷. Serological and repertoire studies
43 from COVID-19 patients have characterized neutralizing antibodies to S protein^{1,2,8,9}. However,
44 the cellular processes that lead to potent neutralizing antibodies in response to mRNA vaccines
45 are not fully characterized and to what degree these antibodies protect against novel variants
46 remains unclear.

47 **Single-cell sequencing of B cells**

48 Nine healthy individuals were included in this study, all naive to prior SARS-CoV-2
49 infection (Extended Data Table 1). One individual contracted symptomatic and PCR-positive
50 COVID-19 eight weeks after the second vaccine. Magnetically enriched peripheral blood B cells
51 were investigated by droplet-based single-cell sequencing prior to the first vaccination (D0), as
52 well as 7-9 days (D7), 21-23 days (D21), and 28 days (D28) after the first vaccination (Fig. 1a).
53 All individuals received their second dose on D21. In addition, SARS-CoV-2 S-specific B cells
54 were labeled with S1, S2, and RBD tetramers conjugated to fluorochromes and DNA-barcodes,
55 and FACS-sorted before sequencing (Fig. 1a). A total of 131,138 B cells (~3600 per sample)
56 were included in the global B cell transcriptomic analysis. Dimensionality Reduction by Uniform
57 Manifold Approximation and Projection (UMAP)¹⁰ and graph-based clustering distinguished
58 nine B cell populations present in all individuals at all four timepoints, including the canonical
59 naïve B cell, unswitched memory (UM) and switched memory (SM) B cell, and plasmablast
60 (PB) clusters (Fig. 1b, Extended Data Fig. 1a-b). Naive B cells and SM were further categorized
61 into resting and activated populations by *CD24* and *CD86* gene expression (Extended Data Fig.
62 1c-e)¹¹. Cluster assignments are supported by isotype proportions and mutation frequencies
63 (Extended Data Fig. 1f-g).



64
 65 **Fig. 1: Single cell transcriptomic analysis of the B cell response following BNT162b2 vaccination.**
 66 **a**, Outline of experimental approach. **b**, UMAP visualization of single-cell B cell transcriptome sequencing
 67 data of all individuals at four timepoints. B cell cluster assignments are based on gene expression and
 68 cell surface expression (CITE-seq) of canonical B cell markers. **c**, Mean percentages of B cell subtypes
 69 shown in **(b)**. **d**, Individual and mean percentages of B cell types in **(b)** at four timepoints. $n=9$ individuals
 70 at all timepoints. Individual values, means and standard deviations are shown. $**P<0.01$, $***P<0.001$,
 71 $****P<0.0001$ according to two-tailed one-way ANOVA test in comparison to the first timepoint.


72 **Unswitched memory (UM) differentiation into resting memory B cells (RSM) in response to**
 73 **vaccination**

74 To evaluate changes in the B cell transcriptome in response to the mRNA vaccine, B cell
 75 subtypes were followed over time (Fig. 1b-d). Strikingly, UM decreased after the initial

76 vaccination, while RSM expanded (Fig. 1c,d). To track the diminishing UM, we followed
77 clonally expanded UM from D0 to the post-vaccination timepoints by their clonal B cell receptor
78 (BCR) sequences (Fig. 2a). Pre-vaccine UM develop into RSM in response to vaccination, with
79 no significant change in mutation load (Fig. 2a, Extended Data Fig. 2a-b), suggesting
80 differentiation without germinal center (GC) maturation. Clonal UM and RSM have little
81 connectivity to PB or activated switched memory (ASM) B cell clusters, indicating activation
82 and differentiation of UM is independent of the antibody response against SARS-CoV-2 (Fig. 2a,
83 Extended Data Fig. 2c). Pathway enrichment analysis of UM and RSM determined significant
84 changes in leukocyte activation, cytokine signaling, and B cell signaling pathways post
85 vaccination (Extended Data Fig. 3a,b). Accordingly, we observed increased expression of B cell
86 signaling and activation genes in UM (Fig. 2b). In contrast, we observed downregulation of the
87 same genes in RSM after vaccination (Fig. 2c). However, upregulation of CD83 and CD69 in
88 RSM indicates recent activation (Extended Data Fig. 3d,e)^{12,13}. Together, this suggests that
89 vaccination activates UM and induces class-switching and differentiation into RSM, independent
90 of the GC. RSM, once differentiated, downregulate their activation levels.

91 **PB and ASM recruitment in response to vaccination**

92 PB are short-lived, activated B cells that expand in response to antigen stimulation and
93 secrete large amounts of antibodies¹⁴. In contrast to strong PB expansions in other vaccination
94 settings¹⁵, overall PB numbers in our study only slightly increase post SARS-CoV-2 vaccination
95 (Fig. 1d, Extended Data Fig. 4a). To identify B cell populations directly involved in the antigen-
96 specific response, we focused on clonal B cell expansions that include PB at D28 (Fig. 2d).
97 Based on shared BCR sequences, we found strong connectivity between the PB, dividing PB,
98 and ASM subsets (Fig. 2d, Extended Data Fig. 2c). Genes associated with leukocyte activation
99 and protein processing are enriched in PB, consistent with their function as antibody producers
100 (Extended Data Fig. 3c). Enrichment of genes associated with SARS-CoV-2 infection at D21
101 suggests that recognition of viral proteins trigger similar pathways in immunization and infection
102 (Extended Data Fig. 3c). Overall, the majority of genes associated with B cell activation increase
103 over time in response to vaccination (Fig. 2e).



104

105 **Fig. 2: Unswitched memory B cell differentiation and expansion of IgG⁺ plasmablasts in response**
 106 **to vaccination.** **a**, Alluvial plot of B cell trajectories (left) across timepoints and UMAP projection (right) of
 107 clonally expanded B cells that are related to at least one UM at D0. Clonal expansions included have ≥ 3
 108 members at ≥ 2 timepoints. **b-c**, Gene expression in UM (**b**) and RSM (**c**) of genes involved in B cell
 109 signaling and activation. **d**, Alluvial plot of B cell trajectories (left) and UMAP projection (right) of clonally
 110 expanded B cells that are related to at least one PB at D28. Clonal expansions included have ≥ 3
 111 members at ≥ 2 timepoints. **e**, Gene expressions of activation markers in PB. **f**, Percentage of IgG⁺ PB per
 112 individual (n=9), at four timepoints. **g**, Average mutation frequency of IgG⁺ PB per individual (n=9) at four
 113 timepoints. Individual values, means and standard deviations are shown. * $P < 0.05$; or ** $P < 0.01$
 114 according to two-tailed one-way ANOVA test in comparison to the first timepoint.

115

116 In health, a high proportion of peripheral blood PB are IgA⁺ due to ongoing immune
 117 responses at the mucosal barriers. IgG⁺ PB of non-mucosal origin increase during systemic
 118 infection and vaccination^{16,17}. Congruently, we observed an increase in IgG⁺ PB one week after


119 the first and second vaccination, respectively (Fig. 2f, Extended Data Fig. 4b-e), with strongest
120 expansions in the inflammatory subtypes IgG1 and IgG3 (Extended Data Fig. 4c). The average
121 mutation frequencies of IgG⁺ PB decrease over time, indicative of an influx of cells into PB from
122 the naïve B cell pool rather than from memory B cells (Fig. 2g). Together, our results show that
123 clonal PB and ASM are closely connected, and new, low mutation IgG⁺ PB are recruited in
124 response to vaccination.

125 **S-specific B cells expand in response to vaccination**

126 To further characterize the S-specific B cell response to vaccination, we labeled B cells
127 with fluorescently labeled S1, S2, and RBD antigen tetramers, each with unique barcodes, and
128 FACS-sorted tetramer-specific and non-specific IgA⁺/G⁺ PB and IgA⁺/G⁺ SM (Extended Data
129 Fig. 5a). Antigen-specificity of each single B cell could be determined by their barcode after
130 demultiplexing (Extended Data Fig. 6a-d). In contrast to the global PB population (Fig. 1d), and
131 in line with our observation on the IgG⁺ PB population (Fig. 2f), S-specific IgA⁺/G⁺ PB strongly
132 expand one week after the initial vaccination and to a lesser degree after the second vaccination
133 (Fig. 3a, Extended Data Fig. 5b). The S-specific IgA⁺/G⁺ SM response increases over time from
134 D7 to D28 (Fig. 3b, Extended Data Fig. 5d). Both S-specific populations, SM and PB, shift from
135 IgA⁺ to IgG⁺ over time (Fig. 3c, Extended Data Fig. 5c,e).

136 **Differential B cell response to S1 and S2**

137 Vaccine studies have shown that antibody responses against distinct epitopes contribute
138 differentially to immune protection¹⁸. Here, we investigated how the antibody response to each
139 subunit of S varies within B cell subsets and over time. UMAP-analysis revealed that S2-specific
140 B cells are predominantly PB and appear in large numbers as early as D7 (Fig. 3d-f). In contrast,
141 the majority of RBD-specific B cells and B cells that bind S1 but not RBD (S1n) are ASM (Fig.
142 3d,e, Extended Data Fig. 5f). Additionally, the RBD and S1n-specific B cells need longer to
143 develop, accounting for less than 20% of S-specific B cells on D7 and over 50% by D28 (Fig.
144 3d-f.). The S2-specific PB response is highly clonal and IgA1⁺ dominated, while RBD and S1n-
145 specific ASM use predominantly IgG1, and are less clonally expanded than S2 PB (Fig. 3g,h).
146 The rapid recall of S2 and delayed S1 response indicates that the S2 B cell response is a
147 secondary response, while the B cell response to RBD is a primary response.



148 **Fig. 3: Vaccination induces a IgA⁺ anti-S2 response on day 7 followed by IgG⁺ RBD response on**
 149 **days 21 and 28. a-c**, Quantification of flow cytometry data, showing percentages of **a**, anti-S PB, and **b**,
 150 anti-S SM in all B cells at four timepoints. **c**, Percentage of IgG⁺ anti-S SM in all anti-S SM at four
 151 timepoints. $n=9$ individuals per timepoint. Individual data points are averages of two independent
 152 experiments. **d**, UMAP visualization of demultiplexed transcriptomic data of anti-S⁺ and anti-S⁻ sorted B
 153 cells, showing cluster assignments of memory (blue), activated memory (turquoise), and PB (red) (left)
 154 and antigen-specificity to S2 (orange), RBD (green), and S1n (blue) (right). **e-h**, Proportions of sorted
 155 cells shown in **(d)**, separated by antigen and by **e**, cluster distribution, **f**, timepoint, **g**, clonality, and **h**,
 156 isotype. **i**, Plasma IgG levels against S2 (left), RBD (center), and S1 (right) for $n=9$ individuals at four
 157 timepoints. AUC for plasma dilutions are shown. **j**, Plasma neutralization curves (left) and quantification
 158 (NT₅₀) of neutralization titers (right) of $n=9$ individuals at timepoints post vaccination. **k**, V-gene mutation
 159 frequencies (number of mutations per length of V-gene) of B cells specific for S2 (left), RBD (center), and
 160 S1n (right) at timepoints post vaccination. Dashed line indicates the average mutation frequency of sorted
 161 antigen negative B cells. Individual data points represent single B cells from $n=9$ individuals. Means and
 162 standard deviations are shown. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ according to two-tailed
 163 one-way ANOVA test in comparison to the first timepoint displayed and **g-j**, chi-square test.

164 The early S2 PB response is echoed by the early development of anti-S2 plasma
165 antibody titers, which start leveling off at D21. Strikingly, RBD and S1 IgG and IgA titers
166 remain low until day 28, one week after the second vaccination (Fig. 3i, Extended Data Fig. 7a-
167 d). Accordingly, plasma neutralization of SARS-CoV-2 Wuhan-Hu-1 pseudovirus is
168 significantly boosted after the second vaccination (Fig. 3j). As primarily anti-RBD antibodies
169 have the potential to block viral entry into the cell, this differentiation is critical and highlights
170 the importance of the second injection for a protective anti-RBD response. Notably, it is
171 overlooked in studies that focus solely on the anti-S antibody response.

172 Interestingly, one study participant contracted COVID-19 eight weeks after the second
173 vaccination. The individual exhibited the lowest IgG and IgA titers for RBD and the lowest
174 plasma neutralization potency following both vaccine doses in the tested cohort (Extended Data
175 Fig. 8a-c). While this individual did produce B cells with high-affinity neutralizing BCR
176 sequences (P1 in Fig. 4e,f), antibody secretion seemingly did not occur on sufficient levels.
177 Antibody titers did not increase significantly even two weeks after the infection (Extended Data
178 Fig. 8d), suggesting that low antibody titers in this individual are not confined to the mRNA
179 vaccine.


180 **Influx of minimally-mutated anti-RBD B cells**

181 During antigen-specific B cell responses, BCR sequences tend to accumulate mutations
182 during affinity maturation¹⁹. In contrast, neutralizing antibodies from COVID-19 patients show
183 characteristically low mutation rates, indicating recruitment of naïve B cells to the GC in
184 response to a novel antigen that has little structural overlap with previously encountered
185 pathogens²⁰. In our study, D7 B cells specific for any of the three antigens showed mutation
186 frequencies similar to the antigen-negative sorted B cells, suggesting that this initial response
187 stems directly from the memory B cell pool (Fig. 3k). At this early timepoint, S2-specific B cells
188 predominate over RBD and S1n-specific B cells, providing further evidence that the rapid
189 memory recall response is more effective for S2 than S1 (Fig. 3f, k). Consistent with this
190 observation, S2 is more conserved among human pathogenic coronaviruses than S1^{21,22}.
191 Strikingly, at timepoints D21 and D28, with the influx of S1-specific B cells, mutation
192 frequencies decrease (Fig. 3k). Together, these results indicate new recruitment from the naïve B
193 cell pool and short GC maturation in response to the vaccine.

194 Vaccine-induced neutralization of variants

195 To test if these newly-recruited, minimally mutated anti-S antibodies are better at binding
196 the S subunits than the early, highly mutated anti-S antibodies recruited from the memory B cell
197 pool, we expressed 50 representative BCR sequences as recombinant monoclonal antibodies
198 (rmAbs) — 14 from S2-specific, 30 from S1/RBD-specific, and 6 from S1n-specific B cells
199 (Extended Data Table 2). Of those selected antibodies, 8 rmAbs bound S2, 15 rmAbs bound
200 RBD, and 3 rmAbs bound S1 but not RBD, as measured by ELISA and bio-layer interferometry
201 (Fig. 4a and Extended Data Fig. 9). Interestingly, when we compared low and high binding anti-
202 S1 rmAbs (encompassing RBD and S1n) we found that high binding rmAbs show significantly
203 lower mutation frequencies than low binding anti-S1 rmAbs (Fig. 4b). In contrast, mutation
204 frequencies of rmAbs against S2 did not differ significantly between low and high binders (Fig.
205 4c). Additionally, the S2 binders with the highest affinities were derived from D7 PB, while
206 highest affinity antibodies against S1 and RBD stemmed from D21 and D28 (Fig. 4a). S2 is the
207 more highly conserved subunit of S^{22,23} To determine if the rmAbs were cross-reactive to other
208 beta-coronaviruses, we tested the highest binders to RBD and S2 against the spike protein of four
209 pathogenic beta-coronaviruses — HCoV-229E, HCoV-HKU1, HCoV-NL63, HCoV-OC43. Of
210 note, nine of the 12 rmAbs against S2 cross-react with HCoV-OC43 spike protein. Conversely,
211 none of the tested anti-RBD rmAbs are cross-reactive to non-SARS-CoV-2 coronaviruses
212 (Extended Data Figure 10). These results corroborate that anti-S2 B cells originate from a recall
213 memory response to heterologous coronaviruses, while in order to generate protective high-
214 affinity anti-RBD antibodies, maturation of naïve cells to PB and ASM is required. While
215 increased affinity correlating with low mutation frequency is counter-intuitive, it is characteristic
216 for the B cell repertoire in COVID-19 patients^{24,25}, and likely caused by the novelty of S protein
217 with little structural overlap to other pathogens, requiring strong recruitment from the naïve B
218 cell pool.

219 The emergence of novel SARS-CoV-2 variants poses additional challenges to the management
220 of the pandemic, and could jeopardize vaccine efficacy and the prospects of an expeditious
221 return to normalcy. RBD mutations contribute significantly to immune escape. To evaluate the
222 effects of variants on antibody neutralization, we selected ten high-affinity Wuhan-Hu-1-
223 neutralizing anti-RBD rmAbs from three individuals (P1, P2, P6) with different levels of plasma
224 neutralization against delta (Fig. 4d-f). Five different SARS-CoV-2 variants of concern



225
 226 **Fig. 4: Neutralization of SARS-CoV-2 pseudovirus and variants by BNT162b2-induced antibodies.**
 227 a, recombinant mAbs derived from BNT162b2-induced B cells bind S2, S1 RBD, and S1. Two-column
 228 heatmaps show barcoded tetramer sequencing data (PE and APC labeled) represented as centered log
 229 ratio transformed (CLR) counts. Bar graphs show binding of rmAbs generated from the corresponding B
 230 cells, represented as area under the curve (AUC) of serial dilutions, measured by ELISA. Threshold,
 231 represented as 0, was set to the average binding to BSA plus three times the standard deviation of
 232 background binding to bovine serum albumin (BSA). **b-c**, Mutation frequencies (number of mutations per
 233 length of V-gene) of **b**, anti-RBD and S1, and **c**, anti-S2 binding rmAbs from (a). High binding rmAbs are
 234 defined as positive for double-barcoded tetramer binding and AUC >3. **d**, Neutralization curves for rmAbs

235 RBD-3, RBD-4, RBD-14, and RBD11, blocking Wuhan-Hu-1 pseudovirus and variants Alpha+E484K,
236 beta, gamma, epsilon, and delta. **e-f**, Heatmaps indicating **e**, IC₅₀ (ng/ml) for each rmAb (**e**) and **f**, NT₅₀
237 (reciprocal dilution) of D28 plasma of n=9 individuals to the indicated pseudovirus variants. *****P*<0.0001
238 according to unpaired two-tailed t-test.

239

240 were included (Extended Data Table 3) — variants alpha+E484K (B.1.1.7+E484K; N501Y,
241 E484K), beta (B.1.351; N501Y, K417N), and gamma (P.1; N501Y, K417T) share a similar set
242 of RBD mutations, of which N501Y contributes most to immune escape²⁶. A different mutation,
243 L452R, is shared by delta (B.1.617.2; L452R, T478K) and epsilon (B.1.429; L452R), and also
244 promotes escape from antibody neutralization²⁷. Each variant can be neutralized by at least four
245 of the ten rmAbs, highlighting the vaccine's potency to generate at least partial protection to all
246 variants (Fig. 4d,e, Extended Data Fig. 11). Antibody neutralization follows RBD mutations, as
247 antibodies tend to block either alpha, beta, and gamma (N501Y), or delta and epsilon (L452R).
248 Two antibodies (RBD-8 and RBD-11) were broadly neutralizing against all variants. Plasma
249 neutralizations showed significantly lower potency against variants than against Wuhan-Hu-1 in
250 all patients, while trending to a better neutralization of delta and epsilon than of alpha, beta, and
251 gamma (Fig. 4f). Interestingly, while the plasma of individual P6 showed very limited
252 neutralization efficacy to alpha, gamma, and delta, we show that P6 had potent neutralizing B
253 cell clones against all variants. P6, therefore, will likely have an extended level of protection
254 from a recall memory B cell response post vaccine, which is inaccessible to assessment by
255 measuring plasma neutralization.

256

257 **Discussion**

258 Our study provides a detailed characterization of the B cell response to the BNT162b2
259 mRNA vaccine on a single-cell level. Parsing the anti-S1 and S2 responses provides important
260 insights into why the second vaccine dose is vital for protection. Our results demonstrate that the
261 first vaccine dose activates a non-neutralizing recall response predominantly targeting epitopes
262 in the S2 protein subunit, which is conserved across human-pathogenic coronaviruses^{22,23}, while
263 the second vaccine dose is vital to boosting neutralizing B cell responses to S1 and RBD.

264 The vaccination induces two major shifts in distinct B cell subtypes: (i) activation of
265 UM and their differentiation into RSM, and (ii) activation and expansion of S antigen-specific
266 PB and ASM. UM are thought to develop independently of the GC reaction, and possess a
267 polyreactive repertoire for rapid B cell responses²⁸. UM are broadly activated early after
268 vaccination, consistent with a natural or ‘innate-like’ B cell response. The unchanged mutation
269 frequency post differentiation indicates a GC-independent response. Once switched, activation
270 levels in RSM decrease, indicating that they are not further promoting an activated B cell
271 response.

272 In contrast, the antigen-specific PB and ASM response is likely derived from GC-
273 dependent processes. The first vaccination induces an IgA-dominant PB response against S2
274 with high mutation frequencies, which is cross-reactive to the human-pathogenic beta-
275 coronaviruses OC43 and HKU1. Our data are consistent with a recall response of mucosal
276 memory B cells that matured during prior pulmonary coronavirus infections.

277 After this initial response, we observed an influx of minimally mutated ASM on D21 and
278 D28, which target S1 and RBD. We show that low mutation frequency corresponds to high
279 affinity against RBD. mRNA vaccines have been shown to induce robust and prolonged GC
280 reactions, with PB and SM persisting in GC for over three months^{29,30}. Despite their low
281 mutation frequency, the delayed development and the switched phenotype of S1/RBD-specific
282 PB and ASM indicate that they underwent GC maturation. High BCR affinity and a naïve
283 phenotype foster preferential recruitment into GC^{31–33} and high affinity also promotes release
284 from the GC as PB, plasma cells, or memory B cells³⁴. High affinity of minimally mutated BCRs
285 could therefore limit GC maturation to a relatively short time frame.

286 We utilized plasma samples and our low mutation RBD-binding rmAbs to characterize
287 neutralization against several SARS-CoV-2 variants of concern. While we found a significant
288 degree of immune escape, we also identified antibodies with neutralization potency against each
289 variant. Importantly, we observed potent neutralization activity against the highly infectious
290 delta variant, which has quickly become the dominant strain world-wide. Delta-neutralizing B
291 cells were even found in an individual with very limited plasma neutralization potency, fueling
292 hope that even individuals with low neutralizing titers can raise a recall memory response upon
293 infection with delta.

294 Together, our study provides a detailed characterization of the blood B cell response to
295 the BNT162b2 mRNA vaccine. Our data emphasize the importance of the second vaccine dose
296 in inducing generation of anti-S1 RBD antibodies that contribute to neutralization of SARS-
297 CoV-2 variants, including delta.

298 **Figure legends**


299 **Fig. 1: Single cell transcriptomic analysis of the B cell response following BNT162b2**
300 **vaccination. a**, Outline of experimental approach. **b**, UMAP visualization of single-cell B cell
301 transcriptome sequencing data of all individuals at four timepoints. B cell cluster assignments are
302 based on gene expression and cell surface expression (CITE-seq) of canonical B cell markers. **c**,
303 Mean percentages of B cell subtypes shown in **(b)**. **d**, Individual and mean percentages of B cell
304 types in **(b)** at four timepoints. $n=9$ individuals at all timepoints. Individual values, means and
305 standard deviations are shown. $**P < 0.01$, $***P < 0.001$, $****P < 0.0001$ according to two-tailed
306 one-way ANOVA test in comparison to the first timepoint.

307 **Fig. 2: Unswitched memory B cell differentiation and expansion of IgG⁺ plasmablasts in**
308 **response to vaccination. a**, Alluvial plot of B cell trajectories (left) across timepoints and
309 UMAP projection (right) of clonally expanded B cells that are related to at least one UM at D0.
310 Clonal expansions included have ≥ 3 members at ≥ 2 timepoints. **b-c**, Gene expression in UM **(b)**
311 and RSM **(c)** of genes involved in B cell signaling and activation. **d**, Alluvial plot of B cell
312 trajectories (left) and UMAP projection (right) of clonally expanded B cells that are related to at
313 least one PB at D28. Clonal expansions included have ≥ 3 members at ≥ 2 timepoints. **e**, Gene
314 expressions of activation markers in PB. **f**, Percentage of IgG⁺ PB per individual ($n=9$), at four
315 timepoints. **g**, Average mutation frequency of IgG⁺ PB per individual ($n=9$) at four timepoints.
316 Individual values, means and standard deviations are shown. $*P < 0.05$; or $**P < 0.01$ according
317 to two-tailed one-way ANOVA test in comparison to the first timepoint.

318 **Fig. 3: Vaccination induces a IgA⁺ anti-S2 response on day 7 followed by IgG⁺ RBD**
319 **response on days 21 and 28. a-c**, Quantification of flow cytometry data, showing percentages of
320 **a**, anti-S PB, and **b**, anti-S SM in all B cells at four timepoints. **c**, Percentage of IgG⁺ anti-S SM
321 in all anti-S SM at four timepoints. $n=9$ individuals per timepoint. Individual data points are
322 averages of two independent experiments. **d**, UMAP visualization of demultiplexed
323 transcriptomic data of anti-S⁺ and anti-S⁻ sorted B cells, showing cluster assignments of memory
324 (blue), activated memory (turquoise), and PB (red) (left) and antigen-specificity to S2 (orange),
325 RBD (green), and S1n (blue) (right). **e-h**, Proportions of sorted cells shown in **(d)**, separated by
326 antigen and by **e**, cluster distribution, **f**, timepoint, **g**, clonality, and **h**, isotype. **i**, Plasma IgG
327 levels against S2 (left), RBD (center), and S1 (right) for $n=9$ individuals at four timepoints. AUC

328 for plasma dilutions are shown. **j**, Plasma neutralization curves (left) and quantification (NT50)
329 of neutralization titers (right) of n=9 individuals at timepoints post vaccination. **k**, V-gene
330 mutation frequencies (number of mutations per length of V-gene) of B cells specific for S2 (left),
331 RBD (center), and S1n (right) at timepoints post vaccination. Dashed line indicates the average
332 mutation frequency of sorted antigen negative B cells. Individual data points represent single B
333 cells from n=9 individuals. Means and standard deviations are shown. * $P < 0.05$, ** $P < 0.01$,
334 *** $P < 0.001$, **** $P < 0.0001$ according to two-tailed one-way ANOVA test in comparison to the
335 first timepoint displayed and **g-j**, chi-square test.

336 **Fig. 4: Neutralization of SARS-CoV-2 pseudovirus and variants by BNT162b2-induced**
337 **antibodies.** **a**, recombinant mAbs derived from BNT162b2-induced B cells bind S2, S1 RBD,
338 and S1. Two-column heatmaps show barcoded tetramer sequencing data (PE and APC labeled)
339 represented as centered log ratio transformed (CLR) counts. Bar graphs show binding of rmAbs
340 generated from the corresponding B cells, represented as area under the curve (AUC) of serial
341 dilutions, measured by ELISA. Threshold, represented as 0, was set to the average binding to
342 BSA plus three times the standard deviation of background binding to bovine serum albumin
343 (BSA). **b-c**, Mutation frequencies (number of mutations per length of V-gene) of **b**, anti-RBD
344 and S1, and **c**, anti-S2 binding rmAbs from (**a**). High binding rmAbs are defined as positive for
345 double-barcoded tetramer binding and $AUC > 3$. **d**, Neutralization curves for rmAbs RBD-3,
346 RBD-4, RBD-14, and RBD11, blocking Wuhan-Hu-1 pseudovirus and variants Alpha+E484K,
347 beta, gamma, epsilon, and delta. **e-f**, Heatmaps indicating **e**, IC50 (ng/ml) for each rmAb (**e**) and
348 **f**, NT50 (reciprocal dilution) of D28 plasma of n=9 individuals to the indicated pseudovirus
349 variants. **** $P < 0.0001$ according to unpaired two-tailed t-test.




350

351 **Extended Data Figure 1: Classification of UMAP B cell clusters.** **a**, Distribution of B cell


352 clusters for each individual (n=9) included in the study. **b**, Gene and cell surface expression of B

353 cell clusters, represented as heatmap / dot plots. **c**, UMAP embedding of B cells colored by
 354 CD19, CD38, IgD, and CD27 protein expression (blue). **d**, UMAP embedding of naïve B cells
 355 colored by CD38 protein expression (blue), and *CD24* gene expression (red). **e**, UMAP
 356 embedding of memory B cells colored by *CD86* and *PTPN6* gene expression (red). **f**, Average
 357 proportions of isotype subclasses in each B cell cluster in $n=9$ individuals vaccinated individuals
 358 across all timepoints. **g**, Average combined mutation frequency (number of mutations per length
 359 of V-gene) in light chain and heavy chain V-gene regions in $n=9$ individuals in the respective
 360 nine different B cell clusters. Individual values, means, and standard deviations are shown.




361
 362 **Extended Data Figure 2: Characterization of clonal B cell expansions in response to mRNA**
 363 **vaccination. a**, Cells corresponding to clonal expansions shown in (Fig 2a). Number of cells in
 364 each clonal expansion ($n=106$) in each B cell cluster at all four timepoints. Statistics are not
 365 calculated for D0 as each clonal family is set to contain at least one clone at D0 in the UM B cell
 366 cluster. **b**, Average mutation frequency (number of mutations per length of V-gene) of clonal
 367 UM expansions at D0 and clonal RSM expansions at D7, D21, and D28. Each dot represents the
 368 average of each mutation frequency for the clonal family in specified B cell clusters and time.
 369 **c**, Cells corresponding to the clonal expansions shown in (Fig. 2d). Number of cells in each clonal


370 expansion ($n=52$) in each B cell cluster at all four timepoints. Statistics are not calculated for
 371 D28 as each clonal family is set to contain at least one clone at D28 in the PB cluster. Individual
 372 values, and **a,c**, standard error of the means, and **b**, standard deviations are shown. $**P < 0.01$,
 373 $***P < 0.001$, $****P < 0.0001$ according to **a,c**, two-tailed Kruskal-Wallis test and **b**, paired two-
 374 tailed t test.



375
 376 **Extended Data Figure 3: Pathway enrichments and differentially expressed genes in**
 377 **response to mRNA vaccination. a-c**, Gene enrichment signatures of DEGs via Metascape³⁵ in
 378 **a**, UM, **b**, RSM, and **c**, PB for D7 (yellow dots), D21 (turquoise dots), D28 (red dots) versus pre-
 379 vaccination. Dashed line represents $q < 0.01$. **d,e**, Volcano plot of differentially expressed genes
 380 in **d**, USM and **e**, RSM at timepoints D7 (left), D21 (center), and D28 (right) relative to D0.



381
 382 **Extended Data Figure 4: Global PB proportions measured by flow cytometry and scRNA-**
 383 **Seq.** **a,b**, Flow cytometry data, **a**, mean percentages of PB in all B cells at the four indicated
 384 timepoints. **b**, Proportions of IgG⁺ (left), IgA⁺ (center), and IgM⁺ PB (right) of all PB. **c-e**,
 385 scRNA-Seq data, proportions of **c**, IgG subclasses, **d**, IgA subclasses, and **e**, IgM in total PB.
 386 n=9 individual values, means, standard deviations are shown. * $P < 0.05$, ** $P < 0.01$,
 387 *** $P < 0.001$, **** $P < 0.0001$, or exact value according to two-tailed one-way ANOVA test.



388

389 **Extended Data Figure 5: Characterization of sorted SARS-CoV-2⁺ SM B cells and PB, a,**

390 Gating strategy for sorting on live singlet SM and PB based on marker expression: CD3⁻, Cd19⁺,


391 IgD⁻, IgM⁻, CD27⁺. Cells were stained with two antigen-tetramers for each subunit of S (S1, S2,

392 and RBD), respectively, labeled with PE and APC. Double-positive cells were sorted. **b,**


393 Representative flow cytometry plots of S⁺ PB. **c,** Proportion of IgA⁺ (left) and IgG⁺ S⁺

394 PB in all S⁺ PB at the indicated timepoints post vaccination. **d,** Representative flow cytometry


395 plots of S⁺ SM. **e**, Proportion of IgA⁺ S⁺ SM in all S⁺ SM at the indicated timepoints post
396 vaccination. **f**, Dot plots of gene expression of B cell clusters shown in (**Fig. 3d**). **c,e**, n=9
397 individual values, means, and standard deviations are shown. **P*<0.05, ***P*< 0.01, ****P*< 0.001
398 according to two-tailed one-way ANOVA test.




400 **Extended Data Figure 6: Specific binding of S antigen tetramers to sorted cells. a-d**, Single-
401 cell sequencing data analysis of barcodes in de-multiplexed data set. Antigen-positive and
402 negative CD3⁻, Cd19⁺, IgD⁻, IgM⁻, CD27⁺ B cells were mixed during the sort. **a**, Heatmap of
403 centered log ratio transformed (CLR) counts of barcoded PE and APC tetramers with S2, RBD,
404 and S1 for all sorted cells. Inset magnifies the antigen-specific cells used in the analysis. **b**,
405 Correlation of barcoded PE and APC tetramers S2 (top), RBD (middle), and S1 (bottom). **c**,
406 Correlation of barcoded APC tetramers of S1 and RBD. **d**, Correlation of barcoded APC
407 tetramers of S2 and RBD.




408 **Extended Data Figure 7: Plasma reactivity to S protein subunits. a**, Area under the curve
409 (AUC) for anti-S2 IgA (left), anti-RBD IgA (center), and anti-S1 IgA (right) from n=9
410 vaccinated individual plasma samples. **b-d**, Plasma IgG (left) and IgA (right) reactivity to **a**, S2,
411 **b**, RBD, **c**, S1 as determined by ELISA. Graph shows optical density units at 450nm of serial
412 plasma dilutions. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, according to two-tailed one-way ANOVA
413 test.
414




415
 416 **Extended Data Figure 8: Analysis of individual P1 who contracted COVID-19 eight weeks**
 417 **post second vaccination. a-b**, Plasma reactivities of **a**, IgG and **b**, IgA to RBD as measured by
 418 ELISA in serial plasma dilutions (right) and depicted as AUC (left). **c**, Plasma neutralization
 419 titers (left) and neutralization curves for plasma of individual P1 at D7, D21, D28 (right). **d**,
 420 Plasma reactivities to RBD for IgG (left) and IgA (right), on D28 compared to day 120 (D120),
 421 two weeks after COVID-19 diagnosis. P1 is highlighted in red, the other eight individuals are
 422 grey. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ according to **a-c**, two-tailed one-way ANOVA test and
 423 **d**, paired t-test.



425 **Extended Data Figure 9: Binding affinities of anti-RBD, S1n, and S2 rmAbs.** a-c, rmAb-
 426 antigen interaction intensities were measured by bio-layer interferometry with immobilized onto
 427 Octet sensors, and S protein subunits. **a**, RBD, **b**, S1n, and **c**, S2 in solution. Binding curves are
 428 shown for the indicated concentrations of antigen. **d**, Kd values of antibodies shown in a-c.



429 **Data Figure 10: Anti-S2 rmAbs are cross-reactive to other human-pathogenic beta-**
 430 **coronavirus S proteins.** **a**, Binding of anti-S2 and anti-RBD rmAbs to SARS-CoV-2 S2, SARS-
 431 CoV-2 RBD, HCoV-OC43 spike, and HCoV-HKU1 spike, assessed by ELISA and represented
 432 as AUC of optical density measurements of serial dilutions. No binding was observed for HCoV-
 433 229E and HCoV-NL63 spike proteins. Threshold, represented as 0, was set to the average
 434 binding to BSA plus three times the standard deviation of background binding to BSA.
 435



436

437 **Extended Data Figure 11: Neutralization of SARS-CoV-2 Wuhan-Hu-1 pseudovirus and**
438 **variants by rmAbs from vaccinated individuals. a,** Neutralization curves for each selected
439 rmAb against the five strains, measured by luminescence measurement upon SARS-CoV-2
440 pseudoviruses infection of transgenic HeLa cells expressing human ACE2. Pseudovirus strains:
441 Wuhan-Hu-1, Alpha+E484K, Beta, Gamma, Epsilon, and Delta.

Extended Data Table 1. Characteristics of participants in BNT162b2 vaccination study.

Participant	Age	Sex	Race	Ethnicity	Symptoms of BNT162b2		Site of vaccination		Confirmed SARS-CoV-2 infection		Symptoms to SARS-CoV-2 infection
					Dose 1	Dose 2	Dose 1 (site)	Dose 2 (site)	Prior	Post	
P1	36-40	M	Caucasian	Hispanic	Site tenderness	Site tenderness	Left	Left	No	Yes	Loss of smell, muscle aches, and fatigue
P2	21-25	M	Asian	Not Hispanic	Site tenderness	Fever, muscle aches, fatigue, chills	Left	Left	No	No	N/A
P3	31-35	M	Asian	Not Hispanic	Site tenderness, muscle aches	Site tenderness, muscle aches, headache, chills	Left	Left	No	No	N/A
P4	26-30	M	Asian	Not Hispanic	None	Site tenderness, fever, muscle aches, fatigue, chills, loss of appetite	Left	Left	No	No	N/A
P5	31-35	F	Asian	Not Hispanic	Site tenderness	Site tenderness, muscle aches, fatigue, headache	Right	Right	No	No	N/A
P6	46-50	F	Caucasian	Not Hispanic	Site tenderness, site swelling	Site tenderness	Left	Left	No	No	N/A
P7	51-55	F	Asian	Not Hispanic	Site tenderness, muscle aches, fatigue, headache, joint pain	Site tenderness, muscle aches, fatigue, headache, joint pain, fever, chills	Right	Right	No	No	N/A
P8	26-30	F	Caucasian	Not Hispanic	Site tenderness	Site tenderness, site swelling, muscle aches, fatigue, headache	Left	Left	No	No	N/A
P9	36-40	M	Caucasian	Not Hispanic	None	None	Right	Right	No	No	N/A

Extended Data Table 2. SARS-CoV-2 pseudovirus variants used in neutralization assays.

variant name	greek alphabet name	Classification	origin	mutations	RBD mutations (319-541)
B.1.1.7 + 484K	Alpha + 484K	Variant of Concern	UK	Δ69/70, Δ144, E484K, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H	E484K, N501Y
B.1.351	Beta	Variant of Concern	South Africa	D80A, D215G, Δ241/242/243, K417N, E484K, N501Y, D614G, A701V	K417N, E484K, N501Y,
P1	Gamma	Variant of Concern	Japan / Brazil	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I	K417T, E484K, N501Y,
B.1.617.2	Delta	Variant of Concern	India	T19R, T95I, G142D, Δ156/157, R158G, L452R, T478K, D614G, P681R, D950N	L452R, T478K
B.1.429	Epsilon	Variant of Interest	US / California	S13I, W152C, L452R, D614G	L452R

Extended Data Table 3. Expressed rmAbs derived from S⁺ sorted B cells

Antibody ID	Participant ID	Timepoint	IGH VDJ (aa)	IGL VJ (aa)
RBD-1	P6	D28	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQAPGQG LEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRS DDTAVYYCARDFFGGIAAAIVSSSRGFDYWGGTLVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQQL PGTAPKLLIYGNTNRPSGVPDRFSGSKSGTSASLAITGLQAE DEADYYCQSYDSSLRWVFGGGTKLTVL
RBD-10	P2	D28	EMQLVESGGGLIQPGGSLRLSCAASGLIVSNNYMNWVRQAPGKG LEWVSVLYPGGTTYADSVKGRFTISRDNKNTLFLQMNSLRAED AAMYVCAREGRGGAFDIWGRGTMVTVSS	DIQMTQSPSSLSASVGDRTITCQASEDISKYLNWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSGTDFTTISLQPEDLA TYYCLQYDNLPRYTFGGQTKLEIT
RBD-11	P1	D28	QVQLQESGPGLVKPSQTLSTCTVSGGSISSGNYWSWIRQPPGK GLEWIGYIYSGSTYYNPSLKSRTVISVDTSKNQFSLKSSVTAADT AVYYCARSLRYFDWLAERGDWFDPPWGGTLVTVSS	EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPG QAPRLIYDASNRTGIPARFSGSGSGTDFTLTISSLEPEDFA VYYCQQRNLFTFGPGTKVDIK
RBD-12	P5	D28	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQG LEWMGIINPSGGSTSYAQKFGQGRVTMTTDTSTSTVYMELSSLRSE DTAVYYCARGLVVPAAKGDLDYWGGTLVTVSS	EIVMTQSPATLSVSPGEGATLSCRASQSVSSNLAWYQQKPG QAPRLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDF VYYCQQYNNWLYTFGGQTKLEIK
RBD-13	P7	D28	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMHWVRQATGKG LEWVSAIGTAGDTYYPGSVKGRFTISRDNKNTLYLQMNSLRAGD TAVYYCARVLYYYDSSGYKRIYWFYFDLWGRGTLVTVSS	DIQMTQSPSSLSASVGDRTITCRASQSISSYLNWYQQKPG KAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFA TYYCQQSYSTPPWTFGGQTKVEIK
RBD-14	P6	D28	QVQLVESGGGVVQPRSLRLSCAASGFTFSMHWVRQAPGKGLE WWAVISYDGSNKYYADSVKGRFTISRDNKNTLYLQMNSLRAEDT AVYYCAREVSGSGWPIDYWGGTLVTVSS	SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQ APVLVYVYDSDRPSGIPERFSGSNGSNTATLTISRVEAGDEA DYYCQVWDSSEDEVFVGTGKVTVL

RBD-15	P2	D28	QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYVDSVKGRFTISRDNKNTLYLQMNSLRA EDTAVYYCARNFWFGDEGYFDYWGQGLTVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPG QAPRLLIYGASTRATGIPARFSGSGTEFTLTISSLQSEDA VYYCQQYNNWPPYTFGGGKLEIK
RBD-16	P9	D28	EIKLVQSGGGSVQGGSLRLSCAASGFTFSAYWMHWVRQVPGKE PVWVSRIHGDAETTTYVDSVKGRFTISRDNKNTLYLQMNSLRVD DTAVYYCARDRLSFYSGRHTNSDAFEVWGQGTTVTVSS	HSVLTQAPSVAAPGQKVTISCSSGNNNSNIGNNFVSWYQQFP GTAPKLLIYENDKRPSGIPDRFSGSGSATLGITGLQTGD EAFYYCGTWDSSLSTGRVFGGGTKLTVL
RBD-17	P4	D28	QVQLVQSGSELKKGASVKVSCKTSGYPFSTYAMNHWVRQAPGQG LEWMGWINTNTGNPTYAQGFRGRFVFLDTSVSTAYLQISSLKAE DTGVYYCARSRTYYYDRSGYPQDSWGGQGLTVTVSS	DTEMTQSPDSLAVSLGERATITCKSSHLLYSSTNKNLAW YQQRPGQPRLLIYWASTREFGVDRFSGGGSGDTFTLTIS SLQAEDVAVYYCQQYYNTPPTFGGQTKVEIK
RBD-18	P7	D7	EVQLLQSGGQSVRPGGSLRLSCVASGFNFHDYAMSWVRAPPK GLEWVATITGGGTITHYADSLKGRVTISRDISTSTIFLHFHNVRVEDA ALYYCAKVQYQLWLSFPDHWGQGSPIAVSS	SYDLTQSSSLSVSVGQTATITCSGSKVGGYYTSWYRKKLGQ PPIIYQNDRRPSEIPDRFSGSTSGNIASLTITGTHPLDAADY YCQSSDSYNVVFVGGGTTLAVL
RBD-19	P6	D21	QVQLQESGPGVVKPSGTLTCTVSGYSIRDGYFWGWVRQPSGK GLEWIGSVYHSGTTYNPSLKSRLTISVDTSKNQFSLDSSVTAAD TALYYCARGHSSVGN DYWGQALTVTVSS	QSALTQPASVSGSPGQITISCTGSSSDVGDSDLVSWYQKY PGKAPKLIIEVNRKPSGVSNNRFFGSKSGDTASLTIFGLQAE DEADYYCYSHAGSSTWMFGGGTKLTVL
RBD-2	P6	D21	QVQLVQSGAEVKKPGSSVKVSCASGGTFSSYTISWVRQAPGQG LEWMGRIIPILGIANYAQKFQGRVTITADKSTSTAYMELSSLRSED AVYYCARGVVGATPGYFDYWGQGLTVTVSS	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPG QAPRLLIYGASTRATGIPARFSGSGTEFTLTISSLQSEDA VYYCQQYNNWLTFFGGGKLEIK
RBD-20	P7	D7	QVQLVQSGSGVKKPGASVRSVSCIASGYPFSGYALHWLRQAPGQS LEWMWINGGNGNSKYQNFEGRVILSRDTSATIVYMDLTSRSE DTAMYYCARGRAHCNNDGCSWGSDFDCWGQGLTVTVSS	ESVLTQSPGTLTSLSPGERATLSCRASQTIRNNYLAWYQQKPG QATPILLIYGASSRATGIPDRFSGSGTDFTLTISRLEPEDFA MYYCQQYGASPMYTFGGGKLEIK
RBD-21	P9	D28	QITLKEGSPALVQPTQTLALCTFSGFSLTSGGLAVGWIRQPPGQA HQWLALVYWDTKRFNPSLESRLTITKDTSKNQVVLMTNMDPVD TGTYCAHSTGDGYFDDWGQGLTVTVSS	DIQMTQSPSSLSASVGDRTITCRASQSIYNFLNHWYQQKPG KAPKLLIYAASSLQSGVPSRFSGSGTEFILSISLQPEDSA TFFCQQSYNVPYTFGGGKLEIK
RBD-22	P9	D7	EVQLVETGGGLIQGGSLRLSCAASGFTGSDNYMSWVRQAPGK LEWVALIYIGGSTVYADSVKGRFTISRDNKNTLYLQMNTLRVEDTA VYYCARDQGEDGYKDAYDIWGQGTMTVTVSS	DIQMTQSPSSLSASVGDRTITCRASQTITTYLNHWYQQKPGK APKLLIYAASALESGVPSRFSGSGTDFTLTISSLQPEDFAT YVCQQYSIPHFVGGGKLEIK
RBD-23	P7	D28	EVQLLQSGGQSVRPGGSLRLSCVASGFNFHDYAMSWVRAPPK GLEWVATISGGGTVTHYADSVKGRVTISRDISTSTIFLQFNNVKVED AALYYCAKVQYQLWLSFPDHWGQGSPIAVSS	SYDLTQSSSLSVSVGQTATITCSGSKVAQYYTSWYQKKLGQ PPVLIYQNDRRPSDIPDRFSGSTSGNIASLTITGTQPLDAAD YVCQSSDSYDVIFGGGTTLAVL
RBD-24	P8	D28	QLQLQESGGLVVKPSETLSLTCVSGGSISRGSYYSGWIRQSPGK GLEWIGNIYDGYTYNPSLKSRTVMSIDTSKNQFSLQLRSVTAAD TALYYCARAHGPGPPGIAAAAANWYFDLWGRGTLTVTVSS	SYVLTQPPSVSVAPGQTARITCGDDIDTESVHWYQQRPG QAPVLVYDQDTRPSGIPERFSGSNSGDTATLTISRVEGGD EADYYCHVWDSNSNHVVFVGGGKLEIK
RBD-25	P8	D7	QVQLVESGGGVVQPGRSLRLSCVASGFTLSNYLIHWVRQAPGKGL EWWAVVSNDRNEYYADSVKGRLTISRDRSRQTLYLQMNSLRAE DTAVYYCAREGMSVTHDGFDIWGQGTMTVTVSS	QAGLTQPPSVSKGLRQTATLCTGNSNNVGDQGAAWLQQH QGHPPKLLSYRDNNRPSGISERFSASRSGNTASLTITGLHPE DEADYYCSAWDSSLAWVFGGGKLEIK
RBD-26	P8	D7	EVQLVESGGGLVQPGRSLRLSCAASGFTFDNYAMHWVRQVPGK LQWISGIAWNSGSGVYADSVNGRFTISRDNKNSLYLQMNSLRRE DTAFYYCAKDFYPLYYGSGIDWYFDLWGRGTLTVTVSS	QSVLTQPPSASGTPGQRTVITSCSSGSSNIGNNWNWYQQLP GTAPKLLIYSNNQRPSGVPDRFSGSKSDTSASLAISGLQSED EADYYCAAWDDSLKGGVFGGGKLEIK
RBD-27	P4	D28	AVQLVESGGGLVQPGGSLTSCAASGFASDTWMSWVRQAPGK LEWVGRIKNTDGGTTAYAAPVQGRFTISRDRSKNTLYLQVNSLKT EDTAVYYCATDGGGIHLTWGQGLTVTVSS	ENVLTQSPATLSLSPGERATLSCGASQSVSSNYLAWYQQKPG GLAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLEPEDF ALYYCQYGSPPVTFGGGKLEIK
RBD-28	P6	D7	LGQLVQSGGEVRKPGASVKVSCASGYTFTETGIIHWVRQAPGQGL EWMGWISNYNGNTKSAEKFGGRITMTTDTSTTASMELTGLTSD TAVYYCATKHARTGGVTGNWFDWGGQGLTVTVSS	QSALTQPRSVSGSPGQAITISCTGASTDVGRYNYVSWYQQ PGKPPKLVYDVNERPSGVPLRFSGSKSGNTASLTISAVQAE DEADYYCCSYAGSYIFVFGSGTRVTVL

RBD-29	P8	D21	QVLLVESGGGWVKPGSLRLSACAASGFNFSDFYMTWMRQAPGK GLEWVSTLSASSSSVYYADSVRGRFTISRDNAKESVYLHMNTLRP EDMAIYYCARGDLDYWGQGLTVTVSS	DVVMTQSPLSLPVTGLQPASISCRSSQSLVHRDGNLYLWV HQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSDTDFTLKISR VEAEDVGVYYCMQGTHWPPLFTFGPGTKLDIK
RBD-3	P6	D28	QVQLQESGGLVKPSETLSLCTVSGGSISSYYWSWIRQPPGKGL EWIGYIYYSGSTNYNPSLKSRTVTSVDTSKNQFSLKLSSVTAADTA YYCARPFRYDSGSYWDHAFDIWQGTMTVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQ PGTAPKLLIYGNSNRPSGVPDRFSGSGSASLAIITGLQAE DEADYYCQSYDSSLSGWEVFGGGTKLTVL
RBD-30	P4	D21	EVQLVESGGGLVQPPGSLRLSCVASFTEFNGHWTNWRQAPGK GLEWVANMKEDGSIKYYVDSVKGRFTISTDNAKNSLYLQMNSLRD EDTAVYYCARESSYETTIFTGFEIWGQGTMTVTVSS	QAGLTQPPSVSKDLGQTATLCTGDTNNVGDGATWLQQY QGHPKLLSYRNNNRPSGISERLSASRSGKTASLTITRLQPE DEADYYCSAWDSSLSVWVFGGGTKLTVL
RBD-4	P6	D28	QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGHG LEWWMGWMNPNNGTGYAQKFQGRVTMTRNTSISTAYMELSSLR EDTAVYYCARGGRYCSSTNCSYSHVIVDWGQGTMTVTVSS	DIQMTQSPSSLSASVGDRTITCRASQGIKNDLWYQQKPG KAPKRLIFPASSLQSGVPSRFSGSGTEFTLTISSLQPEDF ATYYCQLQHNNYPLTFGGGKTKVEIK
RBD-5	P8	D21	EVQLVESGGGLVQPPGSLRLSACAASGFTFDDYAMHWVRQAPGK LEWVSGISWNSGSGVYADSVKGRFTISRDNAKNSFLQMNSLRAE DTALYYCAKDIGSGYGDYFDYWGQGLTVTVSS	SYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQ APVLVIYDSDRPSGIPERFSGSGNSGNTATLISRVEAGDEA DYCCQVWHSSSDHYVFGTGTKVTVL
RBD-6	P1	D28	QVQLVESGGGVVQPPGSLRLSACAASGFTFSSYGMHWVRQAPGK GLEWVAVISYDGSNKYYADSVKGRFTISRDNKNTLYLQMNSLRA EDTAVYYCAKMGPPYCSGGSCYSGYFDYWGQGLTVTVSS	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSDTDFTTISSLQPEDIA TYYCQQYDNLPTFGGGKTKVEIK
RBD-7	P6	D28	QLQLQESGGLVKPSETLSLCTVSGGSISSSSYYWGIRQPPGK GLEWIGTIYYSGSTYYPNPSLKSRTVTSVDTSKNQFSLKLSSVTAADT AVYYCARRPLRHDSSGYLFDYWGQGLTVTVSS	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQ PGTAPKLLIFVNSNRPSGVPDRFSGSGSASLAIITGLQAE DEADYYCQSYDSSLSVWVFGGGTKLTVL
RBD-8	P1	D28	QVQLVESGGGVVQPPGSLRLSACAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYADSVKGRFTISRDNKNTLYLQMNSLRA EDTAVYYCARDGVTITMVRGVIGPAFDIWQGTMTVTVSS	DIQMTQSPSSLSASVGDRTITCQASQDISNYLNWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSDTDFTTISSLQPEDIA TYYCQQYDNLPTFGGGKTKLEIK
RBD-9	P2	D28	QVQLQESGGLVKASQTLSTCTVSGGSISSGGYYWSWIRQHPGK GLEWIGYIYYSGSTYYPNPSLKSRTVTSVDTSKNQFSLKLRSVTAADT AVYYCARDYGGNSNYFDYWGQGLSVTVSS	DIQMTQSPSSLSASVGDRTITCQASQDITNYLSWYQQKPG KAPKLLIYDASNLETGVPSRFSGSGSDTDFTTISSLQPEDIA TYYCQQYHNLPLTFGGGKTKVEIK
S1n-1	P2	D28	QVQLVESGGGVVQPPGSLRLSACAASGFTFSSNYPLHWVRQAPGK LEWVAVISYDGSNKYYVDSVKGRFTISRDNKNTLYLQMNSLRAED TAVYYCARDGSGGAFDYWGQGLTVTVSS	QSALTQPASVSGSPGQISITISCTGTSSDVGGYNYVSWYQQH PGKAPKLMYDVSNRPSGVSNRFSGSGSGNTASLTISGLQA EDEADYYCSSYTSSTWVFGGGTKLTVL
S1n-2	P4	D21	QVQLQESGGLVKPSGTLSTCAVSGGSISSSNWWSWVRQPPGK GLEWIGEIHSGNTNYNPSLKSRTVTSVDTSKNQFSLKLSSVTAADT AVYYCARRSSASSGWSPLFDYWGQGLTVTVSS	QSALTQPASVSGSPGQISITISCTGTSSDVGSYNLVSWYQQH PGKAPKLMIEGSKRPSGVSNRFSGSGSGNTASLTISGLQA EDEADYYCFSYAGSSTWVFGGGTKLTVL
S1n-3	P7	D28	QVQLQESGGLVKPSETLSLCTVSAISISSGYYWGIRQPPGK LEWIGNIYHSGNTYYPNPSLKSRTVTSVDTSKNQFSLKLSSVTAADTA VYYCARDLRIVVVAAYYFDYWGQGLTVTVSS	QSALTQPASVSGSPGQISITISCTGTSSDVGSYNLVSWYQQH PGKAPKLMIEGSKRPSGVSNRFSGSGSGNTASLTISGLQA EDEADYYCCSYAGSTLYVFGTGKTVL
S1n-4	P7	D7	EVRLVESGGGLVEPGGSLRLSACAASGFTFVHSMNWRQAPGK LEFVASISRNLIDYADSVKGRFTISRDNKNSVFLQMNRLRGED TARYYCVRGDSSSWHLFDYWGQGLTVTVSS	EVVLTQSPDTLSLSPGERAILSCASQSVGNLAWYQQQPG QVPRLLIYGPSRATGIPDRFSGGGSGTDFTLISRLEPEDFA IYYCHQYGYSPWAFGPGTKVEIK
S1n-5	P9	D28	EVQLVESGGGLVQPPGSLRLSCRASGFTFDYAINWVRQAPGK LEWVGFIENEAYGTTDYAASVKGRFTISRDDSNSIAYLQMNSLTT GDTALYYCTRNEPCFGACTTHALDPWGLTVTVSS	EIVMTQSPLSLSVTPGEPASISCRSSQTLTYTNGNNYLDWYL KQKQSPQLLIYLASKRASGVPDRFSGSGSGTDFILKISRVE AEDVGVYYCMQALQAPTFGGTRLEIK
S1n-6	P6	D28	EVQLVESGGGLVPRGGSLRLSACAASGFTFSSYSMNWVRQAPGK LEWVSSISSSTSYIHYADSVKGRFTISRDNARNLSFLQMNSLRAED TAVYYCARDLSNSWYNPHYFDSWGQGLTVTVSS	EIVLTQSPGTLTSLSPGERATLSCRASQSVSNNFLAWYQQK GQAPRLLIYGASSRATGIPDRFSGRSGSGTDFTLISRLEPED FAVYYCQQYGDSPRSFGPGTKVELK

S2-1	P9	D7	EVQLVESGGDSVQPGGSLRLSCAASGFTFSNYVHWVRQAPGK GLVWVSRIREDDGIFTTYADSVKGRFTISRDNARNTVSLQMNSLRAE DSAVYYCVRVKVDADLVTADYWGQGTRVTVSS	QTVVTQEPSLTVSPGGTVTLTCASTGAVTSDFYPNWFQK PGQAPRALIYSTSNKHSWTPARFSGSLLGGKAALTLGAQP EDEAEYFCLLYGGAYVFGGTYVFGTGKVTVL
S2-10	P4	D7	EVQLVQSGAEVKEPESLTKISCKGSGYSFSTYWIWVRQLPGKGL QWMGLIYPDDSDTRSNPTFQQQVMTMSVDKSTDTAYLQWSSLKAS DTAMYFCARRYCPDNTCYLAADFLLWGQGMVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSDVSGSYDYVSWYQQ HPGKAPRLMIYDVTKRPSGVPARFSGSKSGNTASLTISGLRA EDEGHYYCCSYAGRHIYEVFGGGTKLTVL
S2-11	P2	D28	QVQLVESGGGVVQGRSLRLSCAASGFTFSSYAMHWVRQAPGK GLEWVAVISYDGSNKYYVDSVKGRFTISRDNKNTLYLQMNSLRA EDTAVYYCARVSSGSYQGLDYWGQGLTVTVSS	EIVLTQSPDFQSVTPKEKVTITCRASQSISGSSLHWYQQKPDQ SPKLLIKYASQSIGVPSRFSGSGSGTDFTLTINSLEAEDAAA YYCHQSSSLPQTFGQGTKEIK
S2-12	P7	D28	EVQLVQSGAEVKKPGESLEISCKASGYNFTNYIGWVRQMPGKGL EWMGIVYPGDSDRYSPSFQQQVTVISADKSITAYLRWRSLKASDT AMYCARRQYYETDSYYPAAFDIWGQGMVTVSS	DIQMTQSPSSLSASVGERVTITCRASQSISTYLNWYQQKPG KAPKLLIYAASSLQIGVPSRFSGSGSGTAFTLTISSLQPEDFA TYCQQSYTTPWTFGPGTKVEIK
S2-13	P7	D28	QVQLVQSGAELKKGASVSKVSCASGYTFSNFYIHWVRQAPGQG LEWMGRINPIIGSTVYAQKFQGRVTMTRDTSTSTIYELIGLRSEDTA LYYCGKEHDATVAAGGMEGLDHWGQGLTVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNFVSWYQQ HPGKAPKLMYDVTKRPSGVPYRFSGSKSGNTASLTMSGLQ PEDEADYYCCSYAGRYTWVFGGGTKLTVL
S2-14	P7	D7	QVQLVQSGAEVKKPGASVRVSCASGYTFSSFYIHWVRQAPGQG LEWMGRINPIIGSTVYAQKFQGRVTMTRDTSTNTVYIELSSLTSED ALYYCGKEHDATVAEGGMEGLDHWGQGLTVTVSS	QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNFVSWYQQ HPGKAPKLMYDVNKRPSGVPYRFSGSKSGNTASLTMSGLQ PEDEADYYCCSYAGRYTWVFGGGTKLTVL
S2-2	P4	D7	QVQLQESGPGLVKPSGTLSTCTVSGGSINISNWWIWRQSPGK LEWIGEYHGGNTNYPNSLKRVSISVDKSKNQFSLSSVTAADTA VYYCARAMRTENSFDYWGQGLTVTVSS	DIQMTQSPSSLSASVGERVTITCRASQSINIYLSWYQQRP KAPKLLIYGFANLQNGVPSRFSGSGSGTDFTLTITNLQPEDF ATYYCQQTYNIPFTFGPGTKVDIK
S2-3	P5	D7	QVQLRESGPGLVLPSTLSTCTVSGGSISTEGYYWTWIRQHPGR GLEWIGYIYSGSAYNPSLKRVTISIDTSENQFSLRLRSVTAADT ALYFCARDDRLAIVRGAFDIWGQGMVTVSS	EIVLTQSPGILSLSPGERATLSCRASEVSGSSFLAWYQQKPG QAPRLLYMGASYRATGIPDRFSGSGSGTDFTLTIRLEAEDF AVYYCQQYGSPPASFGGQGTKEIK
S2-4	P4	D7	QLQLVESGGGVVQGRSLRVSCAASGFLSTYAMHWVRQAPGK GLEWLADLSYEGSITHYAESVKGFRFTISKDNSKNTLYLQMNSLRTD DTARYYCSRGGIAGREAFDLWGQGMVTVSS	DVVMTQSPSLPVTLGQPASISCRSSQSLVSDGNTYLIWFH QRPQSPRRLIYQVSNRDSGVPDRFSGSGSGTDFTLNINRV EAEVDFYFCMCGTHWPLTFGGGKVEIK
S2-5	P5	D7	EVHLVESGGDLVEPGGSLRLSCAASGFNFGNAWMSWVRQAPGK GLEWVARIKRETDGGATDYAAPVKGRFTISRDDSKSTLYLHMNSLK TEDAAVYYCTTDRRQDYDPQFDCWGQGLTVTVSS	DIVMTQSPDSLTVSLGERATINCKSSQSLSYFNKDYLGW YQKKPGQPPKMLIYWASARASGVPDRFSGSASGTDFTLTIS SLQAEDVAVYYCLQYYTYPRTFGQGTKEIK
S2-6	P9	D28	EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYVHWVRQAPGK GLVWVSRIREDDGIFTTYADSVKGRFTISRDNARNTVSLQMNSLRAE DSAVYYCVRVKVDLVTADYWGQGTRVTVSS	QTVVTQEPSLTVSPGGTVTLTCASTGAVTSDYYPNWFQK PGQAPRALIYSTSNKHSWTPARFSGSLLGGKAALTLGAQP EDEAEYFCLLYGGAYVFGGTYVFGTGKVTVL
S2-7	P4	D7	QVQLQESGPGLVKPSGTLSTCTVSGGSINSYYSWVRQTPGKGL EWIGYIYRGSTNYPNSLKRVTISVDTSRNQFSLKLSVTAADTAV YYCARESDNWFDPWGQGLTVTVSS	DIVMTQSPDSLAVSLGERATIRCKSSQSVMIYNNKNYLAWY QKQPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSL QAEDVAIYYCQQYFNTPTWTFGQGTKEIK
S2-8	P4	D7	QVQLQESGPGLVKPSGTLSTCTVSGASINSYYSWVRQTPGKGL EWIGYIYRGSTNYPNSLKRVTMSVDTSRNQFSLRLNSVTAADT AVYYCARETRDNWFDWGWGQGLTVTVSS	DILMTQSPDSLAVSLGERATIRCKSSQSVMIYNNKNYLAWY YQKQPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSL SLQAEDVAIYYCQQYFNTPTWTFGQGTKEIK
S2-9	P9	D28	EVNLVESGGGSVQPGGSLRLSCEVSGFTFSNGWMSWVRQVPGK GLEWVGRIKSKADGETDYAAPVKGRFTIFRDDSKNTLFLQMNSLL MEDTAVYYCASEPPYAYGRFDYWGQGLTVTVSS	DIQMTQSPSSLSASVGERVTITCRASQNIYSLNHWYQLKPGK APKLLIYAASLTQSGVPSRFSGSGSGTDFTLTISSLQPEDFAT YYCQQSYSLTWTWTFGQGTKEIK

442 **Materials and methods**

443 **Study design, sample collection, and storage**

444 All studies were approved by the Institutional Review Board of Stanford University (IRB-3780),
445 and the studies complied with the relevant ethical regulations. All participants provided written
446 informed consent before participating in the study. Nine healthy individuals were enrolled in the
447 study (Extended Data Table 1). All individuals had undergone routine RT-PCR testing prior to
448 study. None of the participants had been previously diagnosed with SARS-CoV-2 infection.
449 Blood samples were collected in heparin tubes (BD) at four different timepoints including pre-
450 vaccination (D0), 7- to 9 days post initial vaccination (D7), on the day of and prior to the second
451 dose (21- to 23 days post initial vaccination, D21), and 28 to 30 days after initial and 7-9 days
452 after second vaccination (D28). Plasma samples were obtained after centrifugation, and stored at
453 -80°C . Peripheral Blood Mononuclear Cells (PBMCs) were obtained by density gradient
454 centrifugation over Ficoll PLUS media (Cytiva) and stored in cell freezing media (Thermo
455 Fisher Scientific). Plasma samples were aliquoted and stored until use at -80°C .

456 **Generation of barcoded fluorescent antigen tetramers**

457 Recombinant Avi-tag biotinylated SARS-CoV-2 S2 protein (Acro Biosystems, S2N-C52E8-
458 25ug), SARS-CoV-2 RBD (Acro, SPD-C82E9-25ug), and SARS-CoV-2 S1 (Acro, S1N-C82E8-
459 25ug) were mixed with barcoded, fluorescently labeled streptavidin (Biolegend) at a 4 to 1 molar
460 ratios for 45 minutes while rotating. Excess biotin was added to saturate all streptavidin binding
461 sites.

462 **Flow cytometry, cell sorting, and 10X sample preparation**

463 PBMCs were thawed at 37°C , treated for 15min with DNase and washed in complete RPMI.
464 PBMCs were enriched for B cells using the EasySep Human Pan-B Cell Enrichment Kit (Stem
465 Cell Technologies) according to the manufacturer instructions. B cell samples without antigen
466 enrichment were stained with CD19, IgD, CD27, CD38 TotalSeq-C antibodies (all Biolegend).
467 For antigen-sorted B cell samples, cells were stained with the following fluorescently labeled
468 antibodies according to standard protocols: CD19, CD20, CD38 (all BD Biosciences), CD3,
469 CD27, IgM, IgD, (all BioLegend), IgA (Miltenyi Biotec), Sytox blue (Thermo Fisher Scientific),
470 and S-antigen tetramers (Extended Data Fig. 3a,b,d). Additionally, samples were labeled with

471 TotalSeq-C hashtag 1-9 antibodies (Biolegend) for demultiplexing individual samples in
472 downstream analysis. Single cells were sorted with a FACSAria II cell sorter (BD Biosciences)
473 into cooled 1.5 ml tubes (BioRad). FlowJo Version 10.7.1 (BD Biosciences) and R version 3.6.1
474 was used for flow cytometry data analysis.

475 **Droplet-based single-cell sequencing**

476 Using a Single Cell 5' Library and Gel Bead Kit v1.1(10X Genomics, 1000165) and Next GEM
477 Chip G Single Cell Kit (10X Genomics, 1000120), the cell suspension was loaded onto a
478 Chromium single cell controller (10X Genomics) to generate single-cell gel beads in the
479 emulsion (GEMs) according to the manufacturer's protocol. Briefly, approximately 8,000 cells
480 were added to each channel and approximately 4,000 target cells were recovered. Captured cells
481 were lysed and the released RNA was barcoded through reverse transcription in individual
482 GEMs. 5' Gene expression (GEX) libraries, Single Cell V(D)J libraries (1000016), and Cell
483 surface protein libraries were constructed according to manufacturer protocols. Library quality
484 was assessed using a 2200 TapeStation (Agilent). The libraries were sequenced using an Illumina
485 Novaseq6000 sequencer with a paired-end 150-bp (PE150) reading strategy (Novogene).

486 **Single cell RNA-seq data processing**

487 Raw gene expression and cell surface matrices were generated for each sample by the Cell
488 Ranger Pipeline (v.6.0.1) coupled with human reference version GRCh38. Briefly, gene
489 expression analyses of single cells were conducted using the R package Seurat (v4.0.2) to
490 perform data scaling, transformation, clustering, dimensionality reduction, differential expression
491 analyses and most visualization³⁶. The count matrix was filtered to remove cells with >10% of
492 mitochondrial genes or low gene counts (<600 for enriched B cells, <200 for sorted B cells). The
493 normalized data were integrated into one Seurat data file using the IntegrateData function.
494 Principal component analysis was performed using variable genes. We compared the ranking of
495 principle components (PCs) with the percentage of variance and determined the number of first
496 ranked PCs used to perform Uniform Manifold Approximation And Projection (UMAP)¹⁰ to
497 reduce the integrated dataset into two dimensions. Afterwards, the same number of first ranked
498 PCs were used to construct a shared nearest-neighbor graph (SNN), and this SNN used to cluster
499 the cells. For sorted cells, all sorted cells were used in the UMAP projection. For enriched B
500 cells, immune cell clusters were identified using canonical markers. Contaminant cells (non-B

501 cells) were removed and the data was normalized, integrated, and clustered with only the B cells.
502 Specific B cell clusters were identified using canonical B cell markers¹¹(Extended Data Fig. 1).

503 **Identification of differentially expressed genes (DEG) and functional enrichment**

504 We performed differential gene expression testing using the FindMarkers function in Seurat with
505 Wilcoxon rank sum test and the Benjamini–Hochberg method was used to adjust the p-values for
506 multiple hypothesis testing. DEGs were filtered using a minimum \log_2 (fold change) of 0.25 and a
507 maximum FDR value of 0.05. Pathway analysis for the DEGs was conducted using the
508 Metascape³⁵.

509 **VDJ Sequence analysis**

510 BCR VDJ regions were generated for each sample using the Cell Ranger Pipeline (v.6.0.1). BCR
511 sequences were then filtered to include cells that have one light and one heavy chain per cell.
512 Consensus sequences were aligned to germline variable-chain immunoglobulin sequences with
513 IMGT HighV-QUEST v1.8.3³⁷. Clonal expansions were defined based on sharing the same
514 heavy and light chain V and J genes with >70% amino acid identity in heavy and light chain
515 CDR3s.

516 **Recombinant monoclonal antibody (rmAb) production**

517 Heavy chain and light chain variable sequences were codon optimized and cloned into in-house
518 vectors, containing human IgG1 constant region or kappa or lambda constant regions,
519 respectively. Expi293F cells were transfected with heavy chain and light chain plasmids using
520 FectoPro (Polyplus transfection). Media was harvested after seven days, and rmAbs were
521 purified with AmMag Protein A magnetic beads (Genscript,). Antibody concentrations were
522 measured with a nanodrop spectrophotometer (Thermo Fisher Scientific) and human IgG
523 quantitation ELISAs (Bethyl Laboratories).

524 **ELISA**

525 For protein ELISAs, MaxiSorp 384-well plates (Thermo Fisher Scientific) were coated with 1
526 $\mu\text{g/ml}$ recombinant SARS-CoV-2 S2 protein (Acro, S2N-C52H5), SARS-CoV-2 RBD (Acro,
527 SPD-C52H3), or SARS-CoV-2 S1 (Acro, S1N-C52H3), HCoV-OC43 Spike protein (Sino
528 Biological, 40607-V08B), HCoV-HKU1 Spike protein (Sino Biological, 40606-V08B), HCoV-
529 229E Spike protein (Sino Biological, 40605-V08B), HCoV-NL63 Spike protein (Sino

530 Biological, 40604-V08B) in carbonate-bicarbonate buffer at 4°C overnight. Plates were washed 6
531 times with PBST (PBS + 0.1% Tween20) after each step. The plates were blocked with blocking
532 buffer (PBS + 1% BSA) for 1 hour at room temperature. Human plasma was serially diluted, and
533 added for 1 hour at room temperature. Human rmAbs were added at concentrations of 10µg/ml
534 and three 10-fold serial dilutions, and incubated overnight at 4°C. Secondary HRP-conjugated
535 antibodies goat anti-human IgG (Bethyl Laboratories) or HRP-conjugated goat anti-human IgA
536 (Bethyl Laboratories) were applied for 1h at RT, and plates were developed with TMB substrate
537 (Thermo Fisher Scientific), and stopped with 2N sulfuric acid. Plates were read on a GloMax
538 Explorer Microplate Reader (Promega).

539 **Bio-Layer Interferometry**

540 rmAb interactions with S2, RBD, and S1 protein were measured on an Octet Red96e (Fortebio /
541 Sartorius). Association and dissociation curves were measured with rmAbs bound to anti-human
542 IgG Fc Capture (AHC) sensors at 20 nM and antigens in solution at 0, 16.7, 50, 150, and 450 nM
543 in 1x kinetic buffer (Fortebio / Sartorius). BLI analysis software (Fortebio / Sartorius) was used
544 for data processing and analysis. Buffer controls were subtracted from antigen values and curves
545 were fitted globally for each group, consisting of all concentrations of the same ligand.
546 Association and dissociation curves and constants as well as KD values for each antibody were
547 reported and graphed with GraphPad Prism.

548 **Cell culture**

549 Expi293F cells were cultured in 33% Expi293 Expression Medium (Gibco) and 67%
550 Freestyle293 Expression Medium (Gibco). HeLa-ACE2 were kindly provided by of Dennis
551 Burton³⁸ and were cultured in Eagle's Minimum Essential Medium (ATCC, 30-2003) with 10%
552 heat-inactivated FBS (Corning) and 100 U/ml of penicillin–streptomycin (Gibco). Lenti X 293T
553 cells (Takara Bio) were cultured in DMEM (ATCC, 30-2002) with 10% heat-inactivated FBS
554 (Corning) and 100 U/ml of penicillin–streptomycin (Gibco).

555 **Generation SARS-CoV-2 spike pseudotyped lentiviral particles**

556 Pseudotyped lentiviral particles were generated as previously described³⁹. Briefly, LentiX 293T
557 cells were seeded in 10cm plates. After 24 hours, cells were transfected using Fugene
558 transfection reagent (Promega) with pHAGE-CMV-Luc2-IRES-ZsGreen-W, lentiviral helper

559 plasmids (HDM-Hgpm2, HDM-tat1b, pRC-CMV-Rev1b), and wildtype or variant SARS-CoV-2
560 spike plasmids (parent plasmids publicly available from Jesse Bloom lab). After 48 to 60 hours,
561 viral supernatants were collected and spun at 1000xg for 10m to remove cell debris. The
562 lentiviral supernatants were concentrated using LentiX concentrator (Takara) according to the
563 manufacturer's instructions. The lentiviral pellets were resuspended at 20-fold viral increase in
564 EMEM media and stored at -80°C. Virus was titrated on HeLa-ACE2 cells.

565 **Viral inhibition assays**

566 Neutralization assays were performed as previously described³⁹. Briefly, eight-fold serially
567 diluted plasma starting at 1:80 from vaccinated individuals or five-fold serially diluted
568 monoclonal antibodies starting at a concentration of 10µg/ml were incubated with SARS-CoV-2
569 pseudotyped virus for 1 hour at 37°C. The mixture was added to HeLa-ACE2 cells plated the
570 prior day. After ~50 hours post-infection, luciferase activity was measured on a GloMax
571 Explorer Microplate Reader (Promega).

572 **Statistics and software**

573 GraphPad Prism version 8.4.1 and R version 3.6.1 were used for statistical analyses. Statistical
574 tests used and significance levels are indicated in the respective methods section or in the figure
575 legends. Graphical illustrations were created with BioRender.

576 **Acknowledgements:**

577 We thank all study participants who devoted time to our research. We thank Dennis Burton for
578 providing the ACE2-HeLa cells. We thank Matthew Baker for key discussions. We thank
579 Shaghayegh Jahanbani for antibody production. This work was supported by T32 AI007290-35
580 to R.C.B.; National Science Foundation Graduate Research Fellowship to R.C.B; the German
581 Research Foundation (DFG, LA3657/1) to T.V.L.; NIH R01 AR063676 and U19 AI110491 to
582 W.H.R.

583

584 **Competing interests**

585 W.H.R. is a Founder, member of the Board of Directors, and consultant to
586 Atreca, Inc.

587

588

589 **Author contributions**

590 Author contributions: Conceptualization, R.C.B., T.V.L., W.H.R.; Methodology, R.C.B., T.V.L.,
591 N.S.R., L.J.L.; Software, R.C.B., T.V.L.; Validation, R.C.B., T.V.L.; Formal Analysis, R.C.B.,
592 T.V.L.; Investigation, R.C.B., T.V.L.; Resources, R.C.B., T.V.L., W.H.R.; Data Curation,
593 R.C.B., T.V.L.; Writing – Original Draft, R.C.B., T.V.L.; Writing – Review & Editing, R.C.B.,
594 T.V.L., N.S.R., L.J.L., W.H.R.; Visualization, R.C.B., T.V.L.; Supervision, T.V.L., W.H.R.;
595 Project Administration, R.C.B., T.V.L., W.H.R.; Funding Acquisition, R.C.B., T.V.L., W.H.R..

596

597 **Materials Availability**

598 Materials generated in this study will be made available on request and may require a material
599 transfer agreement.

600

601 **Data Availability Statements**

602 The raw sequencing data will be uploaded in the GEO database before final publication.

603 **References**

- 604 1. Amanat, F. *et al.* SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies
605 to NTD, RBD, and S2. *Cell* (2021) doi:10.1016/j.cell.2021.06.005.
- 606 2. Röltgen, K. *et al.* mRNA vaccination compared to infection elicits an IgG-predominant
607 response with greater SARS-CoV-2 specificity and similar decrease in variant spike
608 recognition. *medRxiv* (2021) doi:10.1101/2021.04.05.21254952.
- 609 3. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N.*
610 *Engl. J. Med.* **383**, 2603–2615 (2020).
- 611 4. Vogel, A. B. *et al.* BNT162b vaccines protect rhesus macaques from SARS-CoV-2. *Nature*
612 **592**, 283–289 (2021).
- 613 5. Wrapp, D. *et al.* Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion
614 Conformation. *bioRxiv* (2020) doi:10.1101/2020.02.11.944462.
- 615 6. Huang, Y., Yang, C., Xu, X.-F., Xu, W. & Liu, S.-W. Structural and functional properties of
616 SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. *Acta*

- 617 *Pharmacol. Sin.* **41**, 1141–1149 (2020).
- 618 7. Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2
619 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. *Cell* **183**,
620 1024–1042.e21 (2020).
- 621 8. Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody
622 neutralization. *Nature* (2021) doi:10.1038/s41586-021-03777-9.
- 623 9. Ehling, R. A. *et al.* Single-Cell Sequencing of Plasma Cells from COVID-19 Patients
624 Reveals Highly Expanded Clonal Lineages Produce Specific and Neutralizing Antibodies to
625 SARS-CoV-2. (2021) doi:10.2139/ssrn.3817802.
- 626 10. Becht, E. *et al.* Dimensionality reduction for visualizing single-cell data using UMAP. *Nat.*
627 *Biotechnol.* (2018) doi:10.1038/nbt.4314.
- 628 11. Sanz, I. *et al.* Challenges and Opportunities for Consistent Classification of Human B Cell
629 and Plasma Cell Populations. *Front. Immunol.* **10**, 2458 (2019).
- 630 12. Krzyzak, L. *et al.* CD83 Modulates B Cell Activation and Germinal Center Responses. *J.*
631 *Immunol.* **196**, 3581–3594 (2016).
- 632 13. Maddur, M. S. *et al.* Human B cells induce dendritic cell maturation and favour Th2
633 polarization by inducing OX-40 ligand. *Nat. Commun.* **5**, 4092 (2014).
- 634 14. Bortnick, A. & Allman, D. What is and what should always have been: long-lived plasma
635 cells induced by T cell-independent antigens. *J. Immunol.* **190**, 5913–5918 (2013).
- 636 15. Cho, A. *et al.* Robust memory responses against influenza vaccination in pemphigus
637 patients previously treated with rituximab. *JCI Insight* **2**, (2017).
- 638 16. Fink, K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections.
639 *Front. Immunol.* **3**, 78 (2012).
- 640 17. Mei, H. E. *et al.* Blood-borne human plasma cells in steady state are derived from mucosal
641 immune responses. *Blood* **113**, 2461–2469 (2009).
- 642 18. Krammer, F. The human antibody response to influenza A virus infection and vaccination.
643 *Nat. Rev. Immunol.* **19**, 383–397 (2019).
- 644 19. McKean, D. *et al.* Generation of antibody diversity in the immune response of BALB/c
645 mice to influenza virus hemagglutinin. *Proc. Natl. Acad. Sci. U. S. A.* **81**, 3180–3184
646 (1984).
- 647 20. Dugan, H. L. *et al.* Preexisting immunity shapes distinct antibody landscapes after influenza

- 648 virus infection and vaccination in humans. *Sci. Transl. Med.* **12**, (2020).
- 649 21. Ladner, J. T. *et al.* Epitope-resolved profiling of the SARS-CoV-2 antibody response
650 identifies cross-reactivity with endemic human coronaviruses. *Cell Rep Med* **2**, 100189
651 (2021).
- 652 22. Premkumar, L. *et al.* The receptor binding domain of the viral spike protein is an
653 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. *Sci*
654 *Immunol* **5**, (2020).
- 655 23. Ladner, J. T. *et al.* Epitope-resolved profiling of the SARS-CoV-2 antibody response
656 identifies cross-reactivity with an endemic human CoV. *bioRxiv* (2020)
657 doi:10.1101/2020.07.27.222943.
- 658 24. Kreer, C. *et al.* Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing
659 Antibodies from COVID-19 Patients. *Cell* **182**, 843–854.e12 (2020).
- 660 25. Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639–644
661 (2021).
- 662 26. Li, Q. *et al.* SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune
663 escape. *Cell* **184**, 2362–2371.e9 (2021).
- 664 27. Li, Q. *et al.* The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
665 Antigenicity. *Cell* **182**, 1284–1294.e9 (2020).
- 666 28. Palm, A.-K. E. & Henry, C. Remembrance of Things Past: Long-Term B Cell Memory
667 After Infection and Vaccination. *Front. Immunol.* **10**, 1787 (2019).
- 668 29. Lederer, K. *et al.* SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal
669 Center Responses Associated with Neutralizing Antibody Generation. *Immunity* **53**, 1281–
670 1295.e5 (2020).
- 671 30. Turner, J. S. *et al.* SARS-CoV-2 mRNA vaccines induce persistent human germinal centre
672 responses. *Nature* (2021) doi:10.1038/s41586-021-03738-2.
- 673 31. Zuccarino-Catania, G. V. *et al.* CD80 and PD-L2 define functionally distinct memory B cell
674 subsets that are independent of antibody isotype. *Nat. Immunol.* **15**, 631–637 (2014).
- 675 32. Abbott, R. K. *et al.* Precursor Frequency and Affinity Determine B Cell Competitive Fitness
676 in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. *Immunity*
677 **48**, 133–146.e6 (2018).
- 678 33. Turner, J. S. *et al.* Human germinal centres engage memory and naive B cells after

- 679 influenza vaccination. *Nature* **586**, 127–132 (2020).
- 680 34. Li, X. *et al.* Cbl Ubiquitin Ligases Control B Cell Exit from the Germinal-Center Reaction.
681 *Immunity* **48**, 530–541.e6 (2018).
- 682 35. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-
683 level datasets. *Nat. Commun.* **10**, 1523 (2019).
- 684 36. Hao, Y. *et al.* Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587.e29
685 (2021).
- 686 37. Alamyar, E., Duroux, P., Lefranc, M.-P. & Giudicelli, V. IMGT(®) tools for the nucleotide
687 analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires,
688 polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS.
689 *Methods Mol. Biol.* **882**, 569–604 (2012).
- 690 38. Rogers, T. F. *et al.* Isolation of potent SARS-CoV-2 neutralizing antibodies and protection
691 from disease in a small animal model. *Science* **369**, 956–963 (2020).
- 692 39. Crawford, K. H. D. *et al.* Protocol and Reagents for Pseudotyping Lentiviral Particles with
693 SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12**, (2020).